Etrolizumab for Crohn's Disease

  • Injection under the Skin
  • Limited to 1150 patients
  • 1 Location

This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe Crohn's disease.


Eligibility Checklist

You may be eligible to participate if you meet the following criteria:

  • Ages 18 - 80
  • Male or Female
  • Diagnosed with Crohn’s disease
  • Moderately to severely active Crohn's Disease
  • Have not previously been treated with Entyvio (vedolizumab)
See if you're eligible ›

How You Can Participate

This study is currently accepting candidates. You would receive medical care from Dr. Brian Bressler at GI Research Institute. Answer a few questions to see if you can participate ›


Frequently Asked Questions

How much does it cost?
The treatment and doctor visits are free.
Are traveling expenses covered?
Travel expenses will generally be covered.
I have more questions, who do I ask?
Contact us 1-800-794-6031 or support@discovertherapies.com

Timeline

Here's a timeline of what you can expect:

Fill out quiz

Step 1: Online Pre-screener

Find out if you are a match by answering a few online questions.
Check Your Eligibility ›

Nurse

Step 2: Phone Call with Care Coordinator

Speak with our Care Team specialist to confirm your candidacy.

Baseline appointment

Step 3: Screening Appointment

If you are eligible to continue, you will be given an appointment date and time to come to the clinic for a screening visit.


Other Emerging Treatments

Limited to 1580 Patients

Stopping 5-ASA Therapy in Inactive Crohn's Disease

Robarts clinical trials inc.
Dr. Brian Bressler Dr. Brian Bressler

Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by diarrhea and
abdominal pain. Treatments include:

o 5-aminosalicylates, also known as 5-ASA (e.g. Asacol, Pentasa, Mezavant, Salofalk, and
Salazopyrin)
o Steroids (e.g. Entocort, prednisone)
o Immunomodulators (e.g. Imuran, Purinethol, Rheumatrex)
o Biologics (e.g. Remicade, Humira, Entyvio)

5-ASAs are the most commonly prescribed drug class for CD however there is uncertainty regarding their effectiveness for treating CD. Despite this, doctors continue to prescribe a potentially ineffective treatment which, aside from costs ($23M in Canada/year), possibly delays the use of more effective treatments that could reduce the risk of preventable complications in patients, such as surgery.

The STATIC study is trying to determine if patients who stop taking their 5-ASA do no worse than those who continue taking their 5-ASA. Participants will be monitored for complications, surgeries or hospitalizations. The results of this study have potential to improve the lives of patients, change physician prescribing practice, and reduce health care costs.

Limited to 194 Patients

Specific Carbohydrate and Mediterranean Diets for Crohn's Disease

University of pennsylvania
Dr. Corey Siegel Dr. Corey Siegel

This study is evaluating how effective two diets are the for treatment of Crohn's disease: the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD). Both diets have been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and inflammation in the bowel.

Get Involved

Answer a few questions to see if this new treatment is right for you.

Join Now